Dave Fornell HIMSS

Dave Fornell, editor of DAIC and ITN

Blog | Dave Fornell HIMSS | HIMSS| March 24, 2016

New Trends and Technology at HIMSS 2016

The need for improved efficiency in healthcare and the new requirements of U.S. healthcare reform have rapidly made the Healthcare Information and Management Systems Society (HIMSS) annual meeting into one of the largest medical conferences in the world. More than 1,300 companies exhibited on the expo floor, covering IT for every medical specialty including cardiology, radiology and radiation oncology. 

The major themes this year included how to leverage technology to implement population health initiatives, analytics software, patient engagement, improve connectivity and data/image sharing between disparate IT systems and outside physicians, and how to improve workflow efficiency. 

Analytics software and population health appeared to be the poster children topics of HIMSS 2016. With all of healthcare now migrating to electronic medical record platforms, this data can be mined for business uses such as better management of inventory, procedural room use, imaging utilization, staff performance, radiation dose management, monitoring factors for patient satisfaction and to help identify bottlenecks in patient discharge, door-to-balloon times, STAT radiology reads and what contributes to poor or improved patient outcomes. This data has been available for years at many facilities, but it is the new level of analytics software integration that now makes data mining possible for all these things on one screen using one program. 

Examples of analytics software and how technology can improve workflow on PACS and cardiovascular information systems can be found in the video “What to Look for in PACS Workflow Efficiency.”

However, technology is now much more sophisticated than simply pulling data on what has already happened, and can now help predict what will happen. This is the premise of the new IT arena of population health management. If all the risk factors are known for poor clinical outcomes or that lead to re-admissions, these can be tracked using software for all patients to determine who should be allocated additional, scarce resources. This is especially true for high-cost, high-readmission conditions such as heart failure, COPD and diabetes, or high-volume emergency department (ED) patient presentations, such as chest pain. Population health software starts with pulling the patient’s history, current drugs, diagnoses codes and procedures from the electronic medical record. But, it goes beyond this data to pull relevant information such as socio-economic and environmental considerations based on a patient’s address, access to healthcare based on proximity to clinics or hospitals, how often their prescriptions are filled to determine medication compliance, weather conditions, previous lab results, imaging and procedural reports, and many other factors. The software compares these statistics to local, regional and national averages to determine if a patient is at a higher risk than others for everything from readmissions, bed sores and infection, or to triage which chest pain patients in a busy ED are the most likely to be suffering coronary ischemia rather than gastrointestinal distress.

Some software vendors are taking this model to the next level of predictive analytics using health system-wide data or regional health data exchanges to mine thousands of data points to determine which patients in a county or region would be ideal candidates for pre-emptive care. This includes identifying who might be qualified for CT lung cancer screenings, or who should receive calls from healthcare outreach programs to prevent everything from low-birth weight babies in low-income areas and identifying heart failure patients before they ever present with acute symptoms in an ED.

Watch a video of how the University of Mississippi is using population health to identify high-risk cardiac patients.

Patient engagement has become a major topic of discussion as providers try to figure out how to leverage IT to meet this Stage 3 Meaningful Use requirement. I spoke with third-party health IT experts and visited vendors on the HIMSS expo floor for demonstrations of their technology, which can be viewed in the video “Patient Engagement Technology for Imaging.”

Another Stage 3 requirement is the use of clinical decision support (CDS) software to help reduce the number of unnecessary or inappropriate exams. I received feedback from consultants and had examples of this technology demonstrated by vendors in the video “Examples of Clinical Decision Support for Cardiology and Radiology.”

Related Content

ECRI Institute, mergers and acquisitions service
News | Business| January 17, 2017
ECRI Institute announced a new mergers and acquisitions service that empowers new hospital alliances to control their...
electronic health records, EHR, warfarin therapy management, University of Missouri Health Care, blood thinner
News | Antiplatelet and Anticoagulation Therapies| January 17, 2017
Warfarin is a commonly prescribed blood thinner used to prevent harmful blood clots. However, the drug requires...
Lumedx, CVIS, Baylor Scott & White Health, BHVH, Texas
News | Cardiac PACS| January 17, 2017
Lumedx Corp. recently announced that it has implemented Phase 1 of a long-term, multiphase cardiovascular information...
University of Utah, Frank Sachse, heart failure, LVAD implantation, left ventricular assist device, biomarker, t-system

Two patients may seem equally sick based upon clinical measures, but differences in their heart physiology could predict who has the potential to recover from heart failure. A study carried out by scientists at the University of Utah finds that patients whose hearts have flattened t-tubules have a decreased chance of showing signs of recovery after implanting a mechanical heart pump. Ordinarily, t-tubules in the heart are long, thin, and rounded. Image courtesy of Frank Sachse.

News | Cardiac Diagnostics| January 17, 2017
Investigators at the University of Utah have identified distinct differences in the hearts of advanced heart failure...
Synergy stent, abluminal polymer DES, bioresorbable polymer DES, bioresorbable polymer metallic stent

The Synergy stent is the first FDA cleared drug-eluting stent to use a bioresorbable polymer drug carrier. When the polymer dissolves after about four months, the devices become a bare metal stent. The technology is supposed to reduce the rate of late stent thrombosis due to vessel inflammation caused by durable polymers.

Feature | Stents Bioresorbable| January 17, 2017 | Dave Fornell
One of the big advancements in drug-eluting stent (DES) technology has been the development of bioresorbable polymers
Medtronic, CoreValve Evolut R TAVR system, U.S. IDE Study, TCT 2016
News | Heart Valve Technology| November 03, 2016
Medtronic plc unveiled new clinical data showing that patients treated with the self-expanding CoreValve Evolut R...
congenital heart patients, cardiac cath lab, anesthesia sedation practices, joint document, SCAI, SPA, CCAS
News | Congenital Heart| November 03, 2016
The Society for Cardiovascular Angiography and Interventions (SCAI), the Society for Pediatric Anesthesia (SPA) and the...
open-heart surgery, PCI, percutaneous coronary intervention, NOBLE trial, left main coronary artery disease, LMCAD, TCT 2016
News | Cardiovascular Surgery| November 03, 2016
Coronary artery bypass (CABG) surgery is the standard treatment for revascularization in patients with left main...
SENTINEL trial, transcatheter embolic protection, TCEP, TAVR, stroke, TCT 2016
News | Embolic Protection Devices| November 03, 2016
An international study has found that transcatheter cerebral embolic protection (TCEP) is safe, provides effective...
News | Drug-Eluting Balloons| November 03, 2016
The Spectranetics Corp. announced that it has submitted to the U.S. Food & Drug Administration (FDA) its Pre-Market...
Overlay Init